Harnessing the Power of Precision Medicine to Enhance Responsiveness to Cancer Immunotherapy

11:00 am–12:00 pm
National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi

Feb.
22

Professor Akash Patnaik highlighted the ongoing efforts to enhance the efficacy of immunotherapy for cancer treatment. In addition, he discussed collaborative opportunities (laboratory-based research, clinical trials and education/mentoring) with his translational research program at UChicago.

SPEAKER PROFILE

Akash Patnaik, MD, PhD, MMSc, is a medical oncologist specializing in the care of patients with genitourinary cancers, including prostate, bladder, kidney and testicular cancers. He also has a strong interest in the development of novel therapeutics for treatment of advanced solid tumors.

As an accomplished physician-scientist, Dr. Patnaik's work focuses on translating novel therapies from the laboratory to early stage clinical trials. He is interested in developing personalized patient models of disease in order to interpret therapeutics, develop biomarkers, and help patients make informed decisions about their care.

Dr. Patnaik has received numerous awards and recognitions for his work, which include the John W. Kreider Ph.D. Commencement award in Cell & Molecular Biology, AACR-Astellas Clinical/Translational research award, Harvard-MIT Clinician-Investigator Training Program Fellowship, a Prostate Cancer Foundation Young Investigator Award, and a DOD Prostate Cancer Physician-Researcher Training Award.